Scarica l'app Stockscreener
1.91
3.24%
0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow - MSN
Inovio Pharmaceuticals (NASDAQ:INO) Given "Neutral" Rating at HC Wainwright - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Cervical Dysplasia Treatment Market Size Report 2034, - openPR.com
Inovio aims for BLA submission and FDA file acceptance by year-end 2025 as 3107 data shows sustained surgery reduction - MSN
Inovio Pharmaceuticals Inc. Recovery Linked to Earnings Surprise2025 Market Sentiment & Real-Time Buy Signal Alerts - newsyoung.net
Momentum Screeners Rank Inovio Pharmaceuticals Inc. in Top 5 TodayLong Setup & Low Risk Entry Point Guides - newsyoung.net
Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures - AInvest
INOVIO to Announce Q2 2025 Results on August 12 - MSN
INO.O Surges 13.9%: What's Behind Inovio Pharmaceuticals’ Intraday Spike? - AInvest
Inovio Pharmaceuticals shares surge 22.84% intraday after Q2 earnings report, BLA submission plan, and rating upgrade. - AInvest
Inovio Pharmaceuticals (INO) Surges 19.4% on Earnings Optimism—What's Fueling the Biotech Rally? - AInvest
Inovio Pharmaceuticals Soars 12.28% on Q2 Earnings, Clinical Progress - AInvest
Inovio Pharmaceuticals Second Quarter 2025 Earnings: US$0.61 loss per share (vs US$1.19 loss in 2Q 2024) - Yahoo Finance
Inovio rises after promising Q2 results - MSN
Inovio Pharmaceuticals : Second Quarter 2025 Financial Results Conference Call Q2 2025 Financial Results Presentation - MarketScreener
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - The Globe and Mail
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛
Inovio Pharmaceuticals: HC Wainwright Raises PT to $3 from $3, Maintains Neutral Rating. - AInvest
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year - Investing.com
Inovio Pharmaceuticals Q2 2025 Earnings Call Highlights: BLA Submission, Financial Challenges, and Regulatory Progress - AInvest
Inovio Pharmaceuticals Inc. Stock Rallies 14.1%, Outperforms Competitors - 富途牛牛
Inovio Pharmaceuticals shares rise 13.76% intraday after reporting Q2 2025 financial results and progress on INO-3107. - AInvest
Inovio Pharmaceuticals Q2 Results: Net Loss Narrows to $0.61 per Share - AInvest
Inovio rises after promising Q2 results (INO:NASDAQ) - Seeking Alpha
Jefferies Upgrades Inovio Pharmaceuticals(INO.US) to Buy Rating, Cuts Target Price to $1.8 - 富途牛牛
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2025 Earnings Call Transcript - Insider Monkey
Jefferies lowers Inovio stock price target to $1.80 from $2.00 By Investing.com - Investing.com Canada
JMP analyst reiterates Market Outperform rating on Inovio stock By Investing.com - Investing.com Canada
Inovio Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Inovio Pharmaceuticals (INO) Targets BLA Submission for INO-3107 by Year-End 2025 - GuruFocus
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - BioSpace
Inovio’s 2025Q2 Earnings Call: Key Contradictions on Regulatory Strategy, Financial Health, and Clinical Trials - AInvest
Inovio Targets BLA Submission, FDA Approval by Year-End 2025 Amid Positive 3107 Trial Results - AInvest
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Inovio Pharmaceuticals Reports Q2 2025 Financial Progress - TipRanks
Inovio Pharmaceuticals 2025 Q1 Earnings Net Loss Narrows 35.4% - AInvest
Inovio: Q2 Earnings Snapshot - Big Rapids Pioneer
Earnings call transcript: Inovio’s Q2 2025 sees reduced losses, stock rises - Investing.com
Transcript : Inovio Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrow - GuruFocus
INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 - Eastern Progress
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | INO Stock News - GuruFocus
Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrowly Beating Estimates - GuruFocus
INOVIO on track to submit BLA for INO-3107 in 2H25, FDA requested rolling submission. - AInvest
INOVIO Reports Second Quarter 2025 Financial Results And Recent Business Highlights - Barchart.com
Major Earnings Expected After the Close Tuesday: CoreWeave, Inovio Pharmaceuticals, Luminar Technologies, and More - AInvest
Options Volatility and Implied Earnings Moves Today, August 12, 2025 - TipRanks
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates - Nasdaq
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) - Yahoo Finance
Clinical Trial Results: Revolutionary RRP Treatment Slashes Required Surgeries from 4 to Less Than 1 Per Year - Stock Titan
Is Inovio Pharmaceuticals Inc. stock overhyped or has real potentialTrade Setups With Clear Risk Limits Highlighted - beatles.ru
Inovio Pharmaceuticals INO Q2 2025 Earnings Preview Upside Ahead on Promising Clinical Trials Results - AInvest
Inovio Pharmaceuticals Inc expected to post a loss of 61 cents a shareEarnings Preview - TradingView
Arch Therapeutics Inc. (ARTH) Product Pipeline Analysis, 2025 Update - GlobeNewswire Inc.
1.55%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):